An Early Clinical Study to Evaluate the Safety and Efficacy of SN301A Cell Injection in the Treatment of Subjects with Glypican-3 (GPC3)-Positive Advanced Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 22 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

16 Dec 2024 According to a Senti Biosciences media release, first patient has been dosed in this trial in mainland China in collaboration with Celest Therapeutics.
25 Nov 2024 Status changed from not yet recruiting to recruiting.
14 Nov 2024 According to a Senti Biosciences media release, Celest plans to enroll patients initially in a pilot trial in mainland China and expects to dose the first patient in Q4 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com